News >

CDK4/6 Inhibition Refined in HR+ Breast Cancer, as Novel Combos Emerge

Gina Columbus
Published: Tuesday, May 01, 2018

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD
The trifecta of CDK4/6 inhibitors in the hormone receptor (HR)-positive breast cancer paradigm has had a significant impact on patient outcomes. The next major advances in the field will likely include combinations with PI3K inhibitors and potentially checkpoint blockade, says, Sara A. Hurvitz, MD.

on Breast Cancer, Hurvitz, director of the Breast Oncology Program, medical director of the Clinical Research Unit, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, shared insight on the 3 CDK4/6 inhibitors approved in HR-positive breast cancer, and looked toward the future of these agents, which will likely include combination strategies.

OncLive: Please discuss your presentation on CDK4/6 inhibitors.

Hurvitz: Dr Slamon and I discussed the CDK4/6 inhibitors story. I spoke about endocrine therapy. Endocrine therapy for breast cancer was actually the first form of targeted therapies; it is targeting the hormone pathway. However, the hormone pathway is implicated by driving breast cancer in two-thirds to three-quarters of breast cancers—so we have a variety of agents that are able to treat this form of breast cancer. However, the problem is that, in the metastatic setting, the vast majority will have progression of their disease or treatment resistance will develop. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication